688298.SH
东方生物
SSE · Healthcare · Medical - Specialties · CN
CNY 18.71
−3.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0B | 947.4M | 827.9M | 820.2M | 8.8B |
| Cost of Revenue | 567.8M | 560.9M | 565.1M | 467.4M | 4.3B |
| Gross Profit | 443.9M | 386.5M | 262.8M | 352.8M | 4.5B |
| Operating Expenses | |||||
| R&D Expense | 214.1M | 230.8M | 290.5M | 260.9M | 511.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 405.1M | 402.3M | 408.1M | 372.4M | 270.7M |
| Selling & Marketing Expense | 189.8M | 191.0M | 188.9M | 162.2M | 485.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 811.6M | 780.9M | 685.4M | 534.9M | 753.6M |
| Cost and Expenses | 1.4B | 1.3B | 1.3B | 1.0B | 5.1B |
| Operating Income (EBIT) | (551.6M) | (582.2M) | (578.8M) | (383.8M) | 2.5B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (552.7M) | (583.5M) | (585.3M) | (404.2M) | 2.5B |
| Income Tax Expense | 22.6M | 13.9M | (16.5M) | 14.0M | 373.3M |
| Bottom Line | |||||
| Net Income | (552.0M) | (573.6M) | (529.0M) | (397.6M) | 2.1B |
| Earnings from Cont. Ops | (575.3M) | (597.4M) | (568.8M) | (418.3M) | 2.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (552.0M) | (573.6M) | (529.0M) | (397.6M) | 2.1B |
| Per Share | |||||
| Basic EPS | (CN¥2.87) | (CN¥2.98) | (CN¥2.69) | (CN¥1.97) | CN¥12.31 |
| Diluted EPS | (CN¥2.87) | (CN¥2.98) | (CN¥2.69) | (CN¥1.97) | CN¥12.31 |
| Revenue Per Share | CN¥5.28 | CN¥4.92 | CN¥4.21 | CN¥4.06 | CN¥52.20 |
| Shares | |||||
| Basic Shares Outstanding | 191.5M | 192.5M | 196.7M | 201.8M | 168.0M |
| Diluted Shares Outstanding | 191.5M | 192.5M | 196.7M | 201.8M | 168.0M |
| Profitability Metrics | |||||
| EBITDA | — | (379.5M) | (375.5M) | (214.5M) | 2.6B |
| D&A | — | 202.8M | 203.3M | 169.3M | 86.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026